Werkgroep Cardiologische centra Nederland

HERMES (Recruiting)

Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with preserved ejection fraction and systemic inflammation
Medicine
Ziltivekimab
Population
Heart failure
Phase
III
Starting year
2022

Director of Study

dr. C.J.W. Borleffs (Cardioloog)
Den Haag, HagaZiekenhuis